Author

Konstantinos Karmiris

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Konstantinos Karmiris  et al.

THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS
THE NATURAL HISTORY OF COVID-19 IN VACCINATED INFLAMMATORY BOWEL DISEASE PATIENTS

Konstantinos Karmiris  et al.

EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS
EFFECTS OF COVID-19 ON EMPLOYMENT IN IBD PATIENTS

Konstantinos Karmiris  et al.

MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS
MENTAL HEALTH, WORK PRESENTEEISM AND EXERCISE IN IBD PATIENTS

Konstantinos Karmiris  et al.

ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS
ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS

Konstantinos Karmiris  et al.

“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS
“REAL WORLD” PRELIMINARY DATA ON THE EFFICACY AND SAFETY OF 16-WEEK INDUCTION THERAPY WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS

Konstantinos Karmiris  et al.

THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION
THE INFLAMMATORY BOWEL DISEASE – DISK TOOL FOR ASSESSING DISABILITY IN INFLAMMATORY BOWEL DISEASE PATIENTS: VALIDATION OF THE GREEK VERSION

Konstantinos Karmiris  et al.

INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY
INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY

Konstantinos Karmiris  et al.

TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE
TOFACITINIBFOR THETREATMENT OFMODERATE - SEVERE ULCERATIVE COLITIS. THE GREEK EXPERIENCE

Konstantinos Karmiris  et al.

THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD
THE NATURAL HISTORY OF COVID-19 IN PATIENTS WITH IBD: A NATIONWIDE STUDY BY THE HELLENIC SOCIETY FOR THE STUDY OF IBD

Konstantinos Karmiris  et al.

PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY
PREGNANCY OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RETROSPECTIVE DATA FROM A GREEK NATIONAL REGISTRY

Konstantinos Karmiris  et al.

PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING
PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING

Konstantinos Karmiris  et al.

PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)
PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)

Konstantinos Karmiris  et al.

THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB

Konstantinos Karmiris  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Konstantinos Karmiris  et al.

Item 1 - 15 / 15
1